Reuters: Regulatory News: U.S. authorities quiz AstraZeneca over Brilinta clinical trial

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Get healthier and fit with celebrity yoga instructor, Sadie Nardini. The course will teach you a 14 day routine so you can maintain a body more free of toxins and extra weight. From our sponsors

U.S. authorities quiz AstraZeneca over Brilinta clinical trial Oct 31st 2013, 09:35 LONDON | Thu Oct 31, 2013 5:35am EDT LONDON Oct 31 (Reuters) - AstraZeneca is being investigated by U.S. authorities over a major clinical trial that was used to win marketing approval for its new heart drug Brilinta. The British drugmaker said on Thursday it had received a civil investigative demand from the U.S. Department of Justice seeking documents and information regarding the so-called PLATO study. AstraZeneca, which highlighted the investigation in its quarterly results statement, gave no further details but said it intended to cooperate with the inquiry. Brilinta is a key new product for the company, although its progress to date has been slow, with sales in the third quarter edging up to $75 million from $65 million in the three months to end-June. A key challenge for Brilinta is the fact that U.S. doctors tend to use high-dose aspirin for cardiovascular patients and clinical trials suggest AstraZeneca's new drug does not work as well in this setting.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions